The University Hospital of South Manchester NHS Foundation Trust is a defunct NHS foundation trust that previously operated Wythenshawe Hospital, a major acute teaching hospital in Wythenshawe, Manchester. Many of the services and facilities previously at Withington Hospital were transferred to Wythenshawe in 2004.

During the past decade, Wythenshawe Hospital conducted 70 clinical trials. In the 10-year time frame, 70 clinical trials started and 25 clinical trials were completed, i.e. on average, 35.7% percent of trials that started reached the finish line to date. In the past 5 years, 34 clinical trials started and 20 clinical trials were completed. i.e. 58.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Wythenshawe Hospital" #1 sponsor was "Vertex Pharmaceuticals Incorporated" with 9 trials, followed by "Boehringer Ingelheim" with 8 trials sponsored, "Institute of Cancer Research, United Kingdom" with 5 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored and "Manchester University NHS Foundation Trust" with 4 trials sponsored. Other sponsors include 72 different institutions and companies that sponsored additional 67 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Wythenshawe Hospital" #1 collaborator was "National Institute for Health Research, United Kingdom" with 3 trials as a collaborator, "University of Manchester" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Cancer Research UK" with 2 trials as a collaborator and "Eastern Cooperative Oncology Group" with 2 trials as a collaborator. Other collaborators include 90 different institutions and companies that were collaborators in the rest 95 trials.

According to Clinical.Site data, the most researched conditions in "Wythenshawe Hospital" are "Cystic Fibrosis" (10 trials), "Breast Cancer" (8 trials), "Idiopathic Pulmonary Fibrosis" (7 trials), "Asthma" (4 trials) and "Carcinoma, Non-Small-Cell Lung" (4 trials). Many other conditions were trialed in "Wythenshawe Hospital" in a lesser frequency.

Most popular intervention types in "Wythenshawe Hospital" are "Drug" (64 trials), "Other" (22 trials), "Procedure" (17 trials), "Device" (13 trials) and "Biological" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (24 trials), "IVA" (8 trials), "ELX/TEZ/IVA" (5 trials), "Carboplatin" (3 trials) and "Nintedanib" (3 trials). Other intervention names were less common.

The vast majority of trials in "Wythenshawe Hospital" are 96 trials for "All" genders, 10 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Wythenshawe Hospital". undefined are not yet recruiting, 11 are recruiting, 16 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 64 completed trials in Wythenshawe Hospital, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Wythenshawe Hospital, 1 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 45 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 16 trials that are defined as “Not Applicable".